REFERENCES
- Panel on Antiretroviral Guidelines for Adults and Adolescent. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 2011. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL002534.pdf. Accessed February 29,2012.
- European AIDS Clinical Society. EACS Guidelines. 2011. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6_english.pdf. Accessed February 29,2012.
- Gazzard BG; on behalf of the BTGWG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563–608.
- Josephson F, Albert J, Flamholc L, et al. Treatment of HIV infection: Swedish recommendations 2009. Scand J Infect Dis. 2009;41(11–12): 788–807.
- Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiologica. 2011;34(2):109–146.
- Recommandations du groupe d'experts avec le soutien du ministere de la Santé et des Sports. Rapport 2010 sur la prise en charge médicale des personnes infectées par le VIH sous la direction du Pr. Patrick Yéni. 2010. http://www.sante.gouv.fr/IMG/pdf/Rapport_2010_sur_la_prise_en_charge_medicale_des_personnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yenpdf. Accessed March 7, 2012.
- Gouvernement du Québec. La thérapie antirétrovirale pour les adultes infectés par le VIH - Guide pour les professionnels de la santé du Québec. In: Ministere de la santé et services sociaux; ed 2010.
- Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treat-ment of adult HIV infection. JAMA. 2010;304(3):321–333.
- Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS (Lond). 2008;22(12)1 389–1397.
- Panel on Antiretroviral Guidelines for Adults and Adolescent. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 2011. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL002111.pdf. Accessed October 2,2012.
- Tenofovir disoproxil fumarate [product monograph]. Foster City, CA: Gilead Sciences; 2012.
- Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS (Lond). 2009;23(12):1547–1556.
- Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. New Engl J Med. 2009;361(23):2230–2240.
- Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417–1426.
- Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. New Engl J Med. 2008;358(6):568–579.
- Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7)1111–1118.
- Trottier B, Machouf N, Thomas R, et al. Effective and safe use of abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir, a novel regimen for HIV therapy. Presented at: International AIDS Society; 2011; Rome, Italy.
- Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49–58.
- Nishijima T, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S. Efficacy and safety of once-daily ritonavir-boosted darunavir plus abacavir/lamivu-dine for treatment-naive patients: A pilot study. AIDS. 2012;26(5):649–651.